• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Advancing Hematologic Care and the Future of Shared Decision-Making

Opinion
Video

Sikander Ailawadhi, MD, discusses how the studies presented at ASH 2024 highlight significant unmet needs in hematologic cancer management, emphasizing the potential for these findings to influence future clinical practices and shared decision-making models, while identifying key areas for further research and collaboration to improve patient outcomes.

Video content above is prompted by the following:

  • In what ways do these studies’ data collectively advance our understanding of unmet needs in hematologic cancer management, and how can their findings shape future clinical practices?
  • How can the findings presented at ASH 2024 shape the next generation of shared decision-making models for patients with hematologic cancers?
  • What are some key areas where you think further research and collaboration are needed to continue improving patient outcomes?

Related Videos
5 experts are featured in this series
5 experts are featured in this series
1 expert is featured in this series.
5 experts are featured in this series.
5 experts are featured in this series.
Related Content
Red blood cells | Image credit: wanchalerm – stock.adobe.com

Targeted Therapy in CLL May Impact Blood Cell Behavior

January 31st 2025
Article

Research found that ibrutinib reduces red blood cell aggregation in patients with chronic lymphocytic leukemia (CLL), while obinutuzumab/venetoclax does not significantly alter blood viscosity.

Read More

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

December 17th 2024
Podcast

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

Listen

Chromosomes with Telomere floating on blue background | Image credit: peterschreiber.media – stock.adobe.com

Venetoclax Shows Good Results Even in Short-Telomere Patients With CLL

January 21st 2025
Article

New data suggest venetoclax may offset the negative prognostic impact of short telomeres in patients with chronic lymphocytic leukemia (CLL).

Read More

chronic lymphocytic leukemia | Image credit: LASZLO – stock.adobe.com

BTKi Resistance Mechanisms, Solutions Probed at ASH

January 15th 2025
Article

One study found most—but not all—patients with chronic lymphocytic leukemia disease progression while taking a Bruton tyrosine kinase inhibitor (BTKi) had a key mutation linked to resistance.

Read More

Ibrutinib packaging | Image credit: CLShebley – stock.adobe.com

Ibrutinib Safe and Effective in Patients With CLL/SLL, Real-World Data Show

January 10th 2025
Article

The long-term safety of ibrutinib was proven in patients with newly diagnosed or relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

Read More

Patient with leukemia receiving treatment | Image credit: tonefotografia – stock.adobe.com

Patient-Reported QOL Outcomes of Initial CLL Treatments: ASH 2024

January 8th 2025
Article

Quality-of-life (QOL) outcomes vary widely for patients receiving first-line treatment for chronic lymphocytic leukemia (CLL), according to research presented at the 2024 American Society of Hematology (ASH) meeting.

Read More

© 2025 MJH Life Sciences
AJMC®
All rights reserved.